Antibiotic resistance is recognized as one of the biggest global health threats. At present, the management of bloodstream infections typically commences with empirical treatment using a broad-spectrum antibiotic. However, the adjustment of the treatment strategy based on resistance test findings for the infecting bacterium often takes place only after a few days into the therapy. The current antibiotic susceptibility tests (AST) are marred by delays attributed to bacterial growth, which not only facilitate the propagation of antimicrobial resistance but also worsen patient outcomes.
Resistell is developing a ground-breaking technology platform to cater to the critical need for rapid AST of bacteria – independent of the constraints posed by bacterial growth on the time to result.
This webcast will describe how cellular vibrations at the nanoscale, known as nanomotions, provide insights into the health and functioning of cells and can be used to monitor the efficacy of antimicrobials and drugs. Machine learning is used to develop classification models used in nanomotion-based rapid AST. The platform is currently being assessed in the context of bacteraemia/sepsis and M. tuberculosis.
Resistell’s expertise extends beyond AST for Gram-negative and Gram-positive pathogens. The nanomotion technology offers advantages for assessing resistance and susceptibility in slow-growing bacteria and non-growing phenotypes. Nanomotion can also indicate the impact of bacteriophages, as well as drug efficacy on fungi and cancer cells, suggesting a future application for rapid susceptibility testing for phage, antifungal and anticancer therapeutics.
• Principles of the nanomotion technology to assess vibrations of cells
• How bacterial nanomotions can be combined with machine learning to develop an AST
• The future of nanomotion-based testing
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Resistell AG, who retails sole responsibility for content. About this content.
Gilbert Greub, Head and Director, Institute of Microbiology at the University Hospital of Lausanne
Prof. Gilbert Greub, MD, PhD is the current director of the Institute of Microbiology of the University Hospital of Lausanne (Switzerland). He is also Chef de Service and head of medical microbiology at the University Hospital of Lausanne. His activities mainly include research, teaching, & diagnostics as a microbiologist, as well as patient care as an infectious disease specialist. Gilbert Greub has more than 800 publications with more than 23,000 citations.
Rafael Cantón, Head, Clinical Microbiology Department at the University Hospital Ramón y Cajal
Prof. Dr. Rafael Cantón is the Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal (Madrid, Spain) and is Associated Professor of Clinical Microbiology at Complutense University of Madrid. His clinical and research work is focused on antimicrobial resistance mechanisms, antimicrobial susceptibility testing, respiratory tract infections and interplay of clonal epidemiology and resistance. Rafael Cantón has more than 1,000 publications with more than 38,000 citations.
Alex Sturm, Chief Science Officer, Resistell AG
Alex Sturm completed his PhD in Microbiology with focus on Salmonella virulence at the ETH in Zurich. He subsequently moved to New York to study antibiotic tolerance at Columbia University before working on Tuberculosis at the Broad Institute of MIT and Harvard. Since 2021 he is CSO of Resistell AG.
Nikki Forrester, Freelance Science Writer and Editor
Nikki Forrester is a science journalist who covers biology, natural history, climate, and the culture of academic research. She earned a Ph.D. in ecology and evolutionary biology in 2019.